重症患者首剂万古霉素药代动力学指导给药与经验性给药对AUC靶目标达成的影响
该回顾性队列研究纳入66例无急性肾损伤的重症成人患者,比较基于首剂后两次血药浓度计算个体化药代动力学参数指导后续给药与经验性群体估算给药在稳态AUC目标达成上的差异。结果显示首剂药代动力学组稳态AUC达标率显著高于经验性给药组(58.6% vs 32.4%,p=0.033),且AUC变异度更小,但两组48小时内急性肾损伤无差异。
要点
- 首剂后两次万古霉素浓度指导个体化给药可提高稳态AUC达标率。
- 经验性群体估算给药组AUC变异度更大,达标率更低。
- 两种给药方案在稳态浓度后48小时内急性肾损伤无差异。
核心结论
- 在肾功能相对稳定的重症成人中,首剂后两次万古霉素浓度计算个体化药代动力学参数指导后续给药,较经验性给药获得更高的稳态AUC目标达成率。
研究设计与样本
- 回顾性队列研究,纳入66例入住内科ICU、无急性肾损伤且至少两次稳态浓度用于AUC计算的重症成人患者。
主要发现
- 首剂药代动力学组稳态AUC达标率58.6%,经验性给药组32.4%,差异有统计学意义(p=0.033)。
- 经验性给药组AUC变异系数40.7%,首剂药代动力学组26.1%。
- 两组在稳态浓度后48小时内急性肾损伤发生率无差异。
关键数值与推荐
- AUC目标范围为400-600 mg·h/L,评估时间为稳态。
临床怎么用
- 对肾功能相对稳定的重症成人,可考虑首剂后采集两次万古霉素血药浓度,计算个体化药代动力学参数指导后续给药以提高稳态AUC达标率。
局限性
- 回顾性设计,样本量66例,仅纳入肾功能相对稳定且无急性肾损伤的重症成人,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early attainment of target area under the curve (AUC) to minimum inhibitory concentration (MIC) ratios have been associated with clinical success, as well as lower incidence of acute kidney injury (AKI), in patients receiving vancomycin for methicillin-resistant Staphylococcus aureus (MRSA). Critically ill patients are particularly vulnerable to poor outcomes from infection and face multiple risk factors for AKI, thus early precision dosing of vancomycin is vital in this population. We hypothesized that a personalized dosing approach, using vancomycin levels obtained after the first dose to guide further dosing, would be superior to empiric dosing in terms of AUC target attainment assessed at steady state (SS). METHODS: A retrospective cohort study of 66 critically ill adult patients admitted to the medical intensive care unit without AKI and receiving vancomycin with at least two SS concentrations obtained for AUC calculation was performed. Patients were separated into cohorts based on whether they had two concentrations assessed after the first dose of vancomycin and were subsequently dosed based on personalized pharmacokinetic calculations (first-dose kinetics) or whether they were empirically dosed using population estimates. The primary outcome was AUC target attainment (400-600 mg hour/L) at SS. RESULTS: Compared with patients receiving empiric dosing by population estimates, using first-dose kinetics to guide subsequent dosing resulted in significantly greater AUC target attainment at SS (58.6% first-dose vs 32.4% empiric; p=0.033). Patients dosed empirically yielded more variable AUC values across a wide range compared with the first-dose kinetics group (coefficient of variation 40.7% empiric vs 26.1% first-dose). There was no difference in AKI up to 48 hours after SS concentrations between the two dosing schemes. CONCLUSIONS: A dosing strategy using two vancomycin serum concentrations after the first dose and calculating personalized pharmacokinetic parameters to guide subsequent dosing is associated with greater AUC target attainment at SS compared with empiric dosing of vancomycin in critically ill adults with relatively stable renal function.
引用
- Flannery AH, Delozier NL, Effoe SA, et al. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients. Pharmacotherapy. 2020. PMID: 33176005. doi:10.1002/phar.2486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。